inappropriate ADH syndrome: A syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body.
Syndrome of inappropriate secretion of antidiuretic hormone
DOID EFO Endpoint Browser PheWeb
E4_ANTIDIU
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
192 |
4. Check minimum number of eventsNone |
192 |
5. Include endpointsNone |
192 |
6. Filter based on genotype QC (FinnGen only) |
185 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E22
- Name in latin
- Syndroma secretionis impropriae hormonis antidiuretici
Similar endpoints
↥List of similar endpoints to
Syndrome of inappropriate secretion of antidiuretic hormone
based on the number of shared cases.
Similar with more cases:
- Hyperfunction of pituitary gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1631 | 971 | 648 |
| Only index persons | 1405 | 854 | 551 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.56 | 74.37 | 67.48 |
| Only index persons | 72.04 | 74.92 | 67.57 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 185 | 96 | 89 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 69.50 | 69.91 | 69.05 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 192
- Matched controls
- 1920
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E22.2
ICD-10 Finland
Syndrome of inappropriate secretion of antidiuretic hormone
4503599627370496.0
254.0
184
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
83.4
213.1
135
53
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.8
18.6
32
55
AA1AD
NOMESCO Finland
CT of head and brain
3.4
15.2
91
406
H02AB09
ATC
hydrocortisone; systemic
23.4
15.0
21
10
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
7.1
14.9
24
38
R11
ICD-10 Finland
Nausea and vomiting
4.5
12.9
35
90
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
69.3
11.8
13
*
N03AX14
ATC
levetiracetam; systemic
10.6
11.6
22
23
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
127.3
11.6
12
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
5.9
11.1
21
39
N03AG01
ATC
valproic acid; systemic, rectal
5.2
10.0
22
47
S06.3
ICD-10 Finland
Focal brain injury
21.4
10.0
14
7
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.2
9.8
46
172
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.0
9.7
54
223
N30.0
ICD-10 Finland
Acute cystitis
3.2
9.4
43
158
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.8
9.4
62
280
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
12.3
9.3
16
14
N06AX11
ATC
mirtazapine; oral
2.5
8.6
83
449
E87.8
ICD-10 Finland
Other disorders of electrolyte and fluid balance, not elsewhere classified
+∞
8.4
8
*
2536X
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Other disorders of neurohypophysis
+∞
8.4
8
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
8.4
8
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.9
8.4
48
200
N05BA04
ATC
oxazepam; oral
2.5
8.1
68
343
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
8.4
8.1
17
22
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.4
8.0
86
485
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
46.9
7.8
9
*
D64.9
ICD-10 Finland
Anaemia, unspecified
3.1
7.7
36
133
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.9
7.5
15
18
R53
ICD-10 Finland
Malaise and fatigue
2.4
7.4
67
348
A06AD11
ATC
lactulose; oral
2.7
7.0
46
204
M81.9
ICD-10 Finland
Osteoporosis, unspecified
4.4
7.0
18
44
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
9.9
6.9
13
14
J01EA01
ATC
trimethoprim; systemic
2.3
6.8
66
351
G41.9
ICD-10 Finland
Status epilepticus, unspecified
41.6
6.8
8
*
H02AA02
ATC
fludrocortisone; oral
12.9
6.7
11
9
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.1
6.7
31
114
C08CA13
ATC
lercanidipine; oral
2.7
6.7
41
176
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.2
6.6
18
46
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.2
6.5
75
428
N05CF01
ATC
zopiclone; oral
2.2
6.4
81
480
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.5
6.2
22
68
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
9.1
6.2
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
113
136
18.76
98.03
3.3
1.7
413.60
390.56
nmol/l
0.43
101
120
91
403
3.39
15.45
2.7
1.9
2.71
3.18
mg/l
1.41
75
347
133
792
3.21
12.82
8.9
6.3
1.20
1.21
mmol/l
0.57
104
668
110
607
2.90
11.85
3.0
2.5
121.06
131.47
ug/l
0.23
92
547
93
500
2.67
10.10
2.8
2.1
845.44
226.01
u/l
0.45
88
468
133
880
2.66
9.04
10.2
9.0
5.05
4.25
e9/l
1.99
117
776
117
739
2.49
8.61
8.9
5.3
1.21
1.21
mmol/l
0.34
105
663
18
37
5.26
8.55
3.6
2.6
4.64
5.04
kpa
1.89
18
37
18
38
5.12
8.30
1.8
2.0
14.79
15.21
%
—
8
18
28
87
3.60
7.89
7.6
5.6
24.01
25.01
mmol/l
0.69
28
87
57
269
2.59
7.74
2.0
1.9
—
—
—
0
0
109
699
2.29
7.32
4.4
4.4
33.27
35.26
g/l
3.20
100
647
28
95
3.28
6.87
4.0
2.6
1.28
1.28
%
0.01
28
95
27
91
3.29
6.70
4.0
2.5
0.66
0.68
%
0.20
27
91
119
820
2.19
6.35
17.6
16.2
1.24
1.30
inr
0.32
44
224
84
510
2.15
6.17
3.8
2.5
50.16
56.12
u/l
1.02
77
469
42
190
2.55
6.11
2.0
1.8
—
—
—
0
0
120
851
2.09
5.68
7.3
6.1
10.48
10.97
umol/l
0.20
111
799
45
218
2.39
5.63
6.8
5.7
0.78
1.63
mmol/l
0.85
31
170
41
192
2.44
5.52
2.0
1.9
—
—
—
0
0
44
214
2.37
5.44
6.9
5.7
12.08
11.62
kpa
0.26
38
203
44
214
2.37
5.44
6.9
5.7
4.86
5.04
kpa
0.48
38
203
61
344
2.13
5.28
2.1
1.7
1598.62
1244.53
nmol/l
1.38
37
249
100
679
1.99
5.17
5.6
4.1
44.81
46.20
ng/l
0.02
90
519
11
16
7.22
5.03
1.8
1.8
28.27
18.08
ug/l
0.35
11
16
85
552
1.97
4.94
3.2
3.2
1290.42
1575.21
ng/l
0.26
72
467
89
588
1.96
4.91
6.1
3.3
—
—
—
0
0
74
460
1.99
4.86
5.9
3.2
0.46
0.54
e6/l
0.12
68
345
82
530
1.96
4.80
3.1
3.3
2.33
2.35
mmol/l
0.78
72
464
92
621
1.92
4.71
3.2
2.2
82.69
78.76
nmol/l
0.59
81
529
12
22
5.74
4.68
1.8
1.4
92.52
89.45
%
1.50
12
22
24
93
2.81
4.68
5.0
3.5
25.53
24.91
mmol/l
0.49
24
93
13
27
5.08
4.59
1.6
1.4
1.74
1.44
mmol/l
0.36
13
27
15
44
3.61
4.57
1.3
1.6
—
—
—
0
0
25
101
2.70
4.51
4.6
3.8
2.06
1.63
mmol/l
0.22
19
76
150
1204
2.12
4.51
10.0
7.4
83.05
77.89
u/l
0.65
142
1107
12
24
5.26
4.40
1.1
1.0
—
—
—
0
0
140
1101
2.00
4.39
6.3
3.8
15.76
15.03
pmol/l
2.18
128
971
15
46
3.45
4.29
4.4
3.4
7.91
7.82
mmol/l
0.03
15
46
9
13
7.20
4.21
1.3
1.1
—
—
—
0
0
15
47
3.38
4.15
4.4
3.5
1.47
1.49
mmol/l
0.03
15
47
87
602
1.81
3.93
7.5
4.4
—
—
—
0
0
63
394
1.89
3.93
1.8
1.6
22.10
21.06
nmol/l
0.22
53
323
35
177
2.20
3.90
3.2
5.5
236.24
244.20
u/l
0.17
29
165
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
5
12.32
3.79
1.5
1.2
—
—
—
0
0
10
20
5.21
3.74
4.7
3.5
5.56
4.61
e9/l
—
10
20
104
772
1.76
3.61
6.8
4.2
0.00
0.00
estimate
-0.00
34
126
10
21
4.96
3.61
6.2
4.5
69.00
57.00
%
—
10
21
10
21
4.96
3.61
1.3
1.4
—
—
—
0
0
7
9
8.02
3.59
1.1
1.0
—
—
—
0
0
33
169
2.15
3.56
6.6
3.4
—
—
—
0
0
12
31
4.06
3.56
1.3
1.7
—
—
—
0
0
102
761
1.73
3.41
6.8
4.2
0.00
0.00
estimate
-0.00
38
145
102
763
1.72
3.36
8.6
5.7
0.00
0.00
estimate
-0.00
34
133
11
28
4.10
3.34
1.3
1.5
—
—
—
0
0
118
922
1.73
3.29
4.3
3.3
65.03
51.14
u/l
0.59
110
855
64
423
1.77
3.26
7.6
4.4
0.00
0.00
estimate
-0.00
34
129
91
665
1.70
3.23
2.5
2.0
95.93
95.00
pmol/l
0.06
42
328
16
61
2.77
3.22
3.3
2.6
—
—
—
0
0
27
133
2.20
3.20
5.5
5.8
24.44
24.31
mmol/l
0.07
21
125
137
1121
1.78
3.19
6.2
4.1
16.80
13.38
mm/h
1.49
128
1011
13
41
3.33
3.12
1.3
1.7
—
—
—
0
0
13
41
3.33
3.12
1.5
1.3
—
—
—
0
0
7
12
6.01
3.05
1.3
1.0
—
—
—
0
0
7
12
6.01
3.05
1.3
1.0
—
—
—
0
0
5
5
10.22
2.99
1.6
1.2
2.16
1.93
mmol/l
—
5
5
11
34
3.37
2.77
4.5
2.8
94.82
105.76
mmol/l
2.38
11
34
11
34
3.37
2.77
4.5
2.8
4.29
4.07
mmol/l
1.67
11
34
5
6
8.51
2.76
1.6
1.0
—
—
—
0
0
50
325
1.73
2.64
2.1
1.9
432.74
21190057.25
pmol/l
0.50
38
269
11
37
3.09
2.53
1.2
1.5
—
—
—
0
0
20
97
2.19
2.47
1.6
1.4
—
—
—
0
0
10
32
3.24
2.47
1.3
1.6
—
—
—
0
0
10
32
3.24
2.47
1.4
1.1
—
—
—
0
0
100
789
1.56
2.38
2.7
2.7
—
—
—
0
0
24
129
1.98
2.29
4.4
2.4
0.18
0.21
g/l
0.93
18
120
30
175
1.85
2.26
2.0
2.9
6.04
8.75
umol/l
0.68
23
142
8
24
3.43
2.20
1.1
1.1
—
—
—
0
0
10
36
2.87
2.17
1.2
1.3
—
—
—
0
0
8
25
3.29
2.12
1.4
1.7
—
—
—
0
0
5
10
5.10
2.08
2.0
2.2
—
—
—
0
0
47
320
1.62
2.06
3.2
2.9
2.47
2.46
mmol/l
0.12
41
280
7
21
3.42
1.98
1.1
1.5
—
—
—
0
0
166
1509
1.74
1.87
30.3
15.8
25.76
25.46
mg/l
0.04
152
1218
6
17
3.61
1.85
1.0
1.4
—
—
—
0
0
19
102
1.96
1.84
2.8
3.0
63.75
78.52
ng/l
0.35
12
89
5
12
4.25
1.83
1.0
1.1
—
—
—
0
0
5
12
4.25
1.83
2.0
1.9
—
—
—
0
0
88
703
1.46
1.83
3.2
2.6
—
—
—
0
0
8
29
2.83
1.81
1.3
1.3
—
—
—
0
0
6
18
3.41
1.76
2.0
1.1
—
—
—
0
0
22
127
1.83
1.73
2.3
1.6
—
—
—
0
0
10
40
2.58
1.69
1.9
1.4
—
—
—
0
0
152
1368
1.53
1.61
7.2
4.6
1.96
2.00
mu/l
0.15
139
1212
7
26
2.75
1.59
1.4
1.7
—
—
—
0
0
6
20
3.06
1.59
2.0
1.2
—
—
—
0
0
11
51
2.23
1.53
1.5
1.2
—
—
—
0
0
170
1576
1.69
1.51
41.0
18.6
4.08
4.00
mmol/l
3.66
165
1527
7
29
2.47
1.40
1.9
1.5
—
—
—
0
0
9
43
2.15
1.32
2.0
2.0
124.00
123.21
g/l
—
9
29
6
24
2.55
1.31
1.5
1.6
—
—
—
0
0
8
36
2.27
1.26
1.9
1.6
—
—
—
0
0
8
36
2.27
1.26
1.9
1.6
—
—
—
0
0
16
93
1.79
1.25
1.9
1.5
—
—
—
0
0
8
37
2.21
1.23
1.8
1.2
0.16
0.23
g/l
—
8
37
39
288
1.44
1.18
4.8
2.8
0.80
1.15
e6/l
0.72
33
170
12
65
1.90
1.16
1.4
1.3
78.03
172.94
u/ml
1.31
12
55
5
22
2.31
1.04
1.6
1.9
—
—
—
0
0
12
68
1.82
1.03
1.6
3.1
—
—
—
0
0
60
489
1.33
1.01
3.7
3.6
3.88
8.23
mg/mmol
1.71
38
308
18
117
1.59
0.98
4.1
3.3
64.75
60.98
ml/min/173m2
—
8
51
27
194
1.46
0.95
16.3
7.8
—
—
—
0
0
10
56
1.83
0.89
1.6
1.9
—
—
—
0
0
44
353
1.32
0.82
1.5
1.7
1.65
1.46
mg/l
0.15
36
279
45
366
1.30
0.76
3.6
2.2
—
—
—
0
0
50
415
1.28
0.73
2.5
3.1
301.92
9099.03
umol/l
2.69
36
345
7
42
1.69
0.69
1.1
1.5
—
—
—
0
0
34
270
1.32
0.69
5.5
3.0
0.82
2.30
e6/l
1.59
29
155
39
316
1.29
0.68
7.1
3.5
17.00
187.32
ng/l
1.82
34
261
22
163
1.39
0.68
3.0
2.6
4.80
5.17
ug/l
0.11
17
146
165
1576
1.33
0.67
15.5
10.8
25.97
24.46
u/l
0.22
160
1502
37
299
1.29
0.66
1.3
1.2
1.31
0.78
u/ml
—
8
75
8
52
1.56
0.60
1.3
1.8
—
—
—
0
0
25
316
0.76
0.59
2.3
2.9
0.61
0.74
ug/l
0.75
20
211
6
35
1.74
0.58
1.2
1.2
—
—
—
0
0
19
142
1.38
0.57
2.6
2.4
249.66
205.58
ng/l
0.17
19
124
9
62
1.47
0.54
1.6
2.1
—
—
—
0
0
170
1643
1.30
0.51
43.1
22.9
261.87
244.61
e9/l
2.78
165
1591
170
1645
1.29
0.49
43.2
22.9
4.13
4.43
e12/l
10.97
163
1585
170
1645
1.29
0.49
43.7
22.9
35.96
39.67
%
7.92
159
1528
39
451
0.83
0.44
3.5
4.5
20.81
21.40
%
0.08
23
225
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
5
34
1.48
0.40
1.6
1.5
—
—
—
0
0
6
44
1.38
0.34
1.3
1.5
3.54
2.69
mg/l
—
6
34
14
175
0.78
0.32
1.6
1.4
—
—
—
0
0
138
1429
0.88
0.31
4.5
4.6
1.55
1.46
mmol/l
1.68
124
1288
149
1444
1.14
0.29
5.5
5.0
6.16
6.08
mmol/l
0.15
131
1293
17
204
0.82
0.28
3.8
4.7
41.27
31.56
%
1.68
11
131
144
1477
0.90
0.22
5.1
5.3
2.42
2.64
mmol/l
2.37
129
1336
145
1412
1.11
0.21
32.0
14.9
79.99
75.76
ml/min/173m2
1.43
131
1135
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
37
405
0.89
0.21
1.6
1.6
1.17
1.28
mmol/l
0.46
31
336
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
5
66
0.75
0.17
1.0
1.0
—
—
—
0
0
6
79
0.75
0.16
2.0
1.9
—
—
—
0
0
144
1412
1.08
0.14
7.0
6.3
40.96
40.82
mmol/mol
0.05
131
1303
141
1435
0.93
0.12
4.3
4.7
4.29
4.54
mmol/l
2.18
126
1305
20
183
1.10
0.10
1.5
1.4
—
—
—
0
0
136
1377
0.96
0.07
3.9
4.2
1.12
1.28
mmol/l
2.78
121
1234
55
559
0.98
0.02
4.6
5.0
1.93
2.54
ug/l
0.62
48
488
22
224
0.98
0.00
1.3
1.3
18.65
31.66
iu/ml
—
10
75
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
7
73
0.96
-0.00
1.7
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
8.44
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
8.09
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint E4_ANTIDIU and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 2.117 [1.65, 2.72] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.177 |
During the follow-up period (1.1.1998 — 31.12.2019), 348 out of 767 females with E4_ANTIDIU died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 3.366 [2.32, 4.88] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 270 out of 507 males with E4_ANTIDIU died.
Mortality risk
Mortality risk for people of age
years, who have E4_ANTIDIU.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.198% | 0.597% |
| 5 | 1.064% | 3.778% |
| 10 | 2.882% | 8.794% |
| 15 | 5.999% | 16.438% |
| 20 | 10.228% | 26.295% |
Relationships between endpoints
↥Index endpoint: E4_ANTIDIU – Syndrome of inappropriate secretion of antidiuretic hormone
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data